Search results
If You'd Invested $1,000 in Bristol Myers Squibb 5 Years Ago, Here's How Much You'd Have Today
Motley Fool via Yahoo Finance· 4 days agoIt's a reasonable question: If you'd invested $1,000 in pharmaceutical specialist Bristol Myers...
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Zacks via Yahoo Finance· 7 days agoBristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it...
Maximize Your Dividends: 7 Stocks Trading Under $50 with 5%+ Yields
InvestorPlace· 8 hours agoInvesting in dividend stocks is one of the surest paths to building long-term wealth. The good news...
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics - Bristol-Myers Squibb (NYSE:BMY)
Benzinga· 6 days agoLoading... Loading... Financial giants have made a conspicuous bearish move on Bristol-Myers Squibb. Our analysis of options history for Bristol-Myers Squibb BMY revealed 9 unusual trades. Delving ...
Tolerizing vaccines for autoimmune diseases tempt BMS into $1.8bn collaboration
BioPharma-Reporter· 7 days agoBristol Myers Squibb (BMS) has bet up to $1.8bn in a collaboration with Repertoire Immune Medicines...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 9 hours agoNew York, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Global Liver Disease Therapeutics Market to Grow Rapidly by 2030, Examines DelveInsight | Key Players in the Market - AbbVie, GSK, F.Hoffmann-La Roche, Bristol-Myers Squibb Company, Abbott, Gilead
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Morningstar· 6 days agoEditas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers Squibb (NYSE: BMY) under which the parties ...
Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb - Bristol-Myers Squibb...
Benzinga· 7 days agoScenic Biotech, a pioneer in the field of modifier therapies for severe genetic disorders, today announced that it has entered into a research collaboration with Bristol Myers Squibb BMY to ...
Judge rejects J&J, BMS challenges to Medicare drug pricing program
NJBIZ· 5 days agoA federal judge in New Jersey tossed lawsuits from Johnson & Johnson and Bristol Myers Squibb...
Insider Buying: BOERNER CHRISTOPHER S., Bristol-Myers Squibb Co. [BMY] Chief Executive Officer...
Knox Daily· 5 days agoThe buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Bristol-Myers Squibb Co. shares valued at $99,560 were purchased ...